News Sentiment

CLLS sentiment intelligence

Cellectis SA news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.99 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.4% over one week, -3.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -9.4% Price reacting lower
Trend fit Trend inactive -3.2% over four weeks
Fair value 15.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 36
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 8
Market source 6
MarketBeat 4
dars.gov.et 2
GlobeNewswire 2
simplywall.st 2
The Globe and Mail 1

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 21
Analyst action 3
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
Idéal Investisseur Direct company coverage

Cellectis: FDA Grants RMAT Status to Lasmé-cel for B-Cell ALL Leukemia

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to Cellectis' lasmé-cel, an allogeneic CAR-T candidate, for treating relapsed or refractory B-cell acute lymphoblastic leukemia. This designation is based on promising phase 1 data from the BALLI-01 trial, p

Tone
Positive 72/100
Event
Market update
Published
10 Jun 2026 07:10
Source
Idéal Investisseur